- Home
- LPTX vs RBKB Comparison
LPTX vs RBKB Comparison
Compare LPTX & RBKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- RBKB
- Stock Information
- Founded
- LPTX 2011
- RBKB 1860
- Country
- LPTX United States
- RBKB United States
- Employees
- LPTX N/A
- RBKB N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- RBKB Banks
- Sector
- LPTX Health Care
- RBKB Finance
- Exchange
- LPTX Nasdaq
- RBKB Nasdaq
- Market Cap
- LPTX 119.6M
- RBKB 111.3M
- IPO Year
- LPTX N/A
- RBKB 2019
- Fundamental
- Price
- LPTX $0.39
- RBKB $10.31
- Analyst Decision
- LPTX Buy
- RBKB
- Analyst Count
- LPTX 3
- RBKB 0
- Target Price
- LPTX $8.50
- RBKB N/A
- AVG Volume (30 Days)
- LPTX 321.2K
- RBKB 6.1K
- Earning Date
- LPTX 05-12-2025
- RBKB 04-24-2025
- Dividend Yield
- LPTX N/A
- RBKB N/A
- EPS Growth
- LPTX N/A
- RBKB N/A
- EPS
- LPTX N/A
- RBKB N/A
- Revenue
- LPTX N/A
- RBKB $25,911,000.00
- Revenue This Year
- LPTX N/A
- RBKB N/A
- Revenue Next Year
- LPTX N/A
- RBKB N/A
- P/E Ratio
- LPTX N/A
- RBKB N/A
- Revenue Growth
- LPTX N/A
- RBKB N/A
- 52 Week Low
- LPTX $0.39
- RBKB $7.30
- 52 Week High
- LPTX $4.79
- RBKB $10.49
- Technical
- Relative Strength Index (RSI)
- LPTX 18.56
- RBKB 61.09
- Support Level
- LPTX $0.40
- RBKB $10.10
- Resistance Level
- LPTX $0.46
- RBKB $10.43
- Average True Range (ATR)
- LPTX 0.03
- RBKB 0.11
- MACD
- LPTX 0.06
- RBKB 0.01
- Stochastic Oscillator
- LPTX 0.00
- RBKB 71.43
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About RBKB Rhinebeck Bancorp Inc.
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one- to four-family residential real estate loans, and to purchase investment securities.